Shennon Biotechnologies
Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.
$12MFunding
ParticipantSC
Saras Capital
Activity from announced rounds
Activity in this selectionUnited States · Oct 19, 2026 · Jul 22, 2026
Saras Capital is the investor linked by Biographica, Converge and Shennon sources to Nadav Rosenberg.
Recorded funding activity
Biographica develops crop traits using AI discovery. Converge supplies drug-discovery models, while Shennon develops cancer therapies. These company records preserve separate biological applications and financing events.
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $12M 1 disclosed · full round size, not this investor’s share